RecruitingNCT06902194

To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children

Mucosal Surveillance and Immunology of Respiratory Pathogens in South African Children Post the COVID-19 Pandemic


Sponsor

Desmond Tutu TB Centre

Enrollment

250 participants

Start Date

Oct 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to answer a few questions about respiratory tract infections in South African children: 1. How do children with COVID-19 and other respiratory (chest, throat, ear or nose) germs show symptoms? What signs should be looked for, and which children are more likely to get seriously ill? Are there any new germs that haven't been discovered yet? Can immune cells in saliva predict which children will get more severe disease? 2. The body's immune response (soldier- cells) in blood and saliva (spit) will be studied. 3. What is the short-term effect of COVID-19 and other respiratory viruses/ germs on the breathing (lung function) of children? 4. What is the impact of respiratory germs on the quality of life in children and their families? The investigators aim to recruit a minimum of 250 children with respiratory pathogens.


Eligibility

Max Age: 13 Years

Inclusion Criteria1

  • \- Children aged 0-13 years with acute respiratory tract infections presenting to Tygerberg Hospital (TBH) in Cape Town, South Africa, for routine care

Exclusion Criteria1

  • Admitted for \< 72 hours

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Desmond Tutu TB Centre, Tygerberg Hospital

Cape Town, Western Cape, South Africa

Desmond Tutu TB Centre

Cape Town, Western Cape, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06902194


Related Trials